Induced protein degradation can potentially be used to therapeutically modulate previously ‘undruggable’ targets, such as transcription factors. In Cancer Cell, Bai and colleagues now report a ...

Tokyo Medical and Dental University(TMDU) study shows that ruxolitinib-induced inhibition of STAT3 activity blocks survival and reduces pro-inflammatory cytokine production in Epstein-Barr virus (EBV) ...

Triple-negative breast cancer (TNBC) lacks hormone receptors and HER2 amplification, limiting the effectiveness of targeted therapies and contributing to its aggressive clinical behavior. As aberrant ...

Recludix Pharma Inc. has divulged signal transducer and activator of transcription 3 (STAT3) and 6 (STAT6) inhibitors reported to be useful for the treatment of cancer and inflammation.

Figure 1: (A) Canonical STAT3 activation pathway. (B) WP1066 and TTI-101, examples of small molecule STAT3 inhibitors that are cell penetrant. Pediatric H3K27M-mutant diffuse midline gliomas (DMGs), ...

Pooled patients treated with TTI-101 demonstrated a 9.4% decrease from baseline in fibrosis score at week 12, compared to a 2.4% decrease for the ...

With $9 million in series A financing, Tvardi Therapeutics has enough runway to finish a phase 1 trial of its lead asset, an oral STAT3 inhibitor, in solid tumors and to start multiple ...

HOUSTON--(BUSINESS WIRE)--Tvardi Therapeutics, Inc. (“Tvardi”) will publicly present, for the first time, clinical results from the Phase 1 study of TTI-101, a STAT3 inhibitor, in relapsed/refractory ...

A multicenter, single arm phase II trial of a small molecule immune-modulator icaritin: Safety, overall survival, immune dynamics, and PD-L1 expression in advanced hepatocellular carcinoma. This is an ...

TTI-101 is an orally-delivered, small molecule, STAT3 (signal transducer and activator of transcription 3) inhibitor. The Food and Drug Administration (FDA) has granted Orphan Drug designation to ...